Payload Information

General Information of This Payload (ID: PAY0HRHLR)

Name	Deglycosylated ricin A-chain (dgA)
Synonyms	Deglycosylated ricin A-chain (dgA) Click to Show/Hide

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	124	ug/mL	Daudi cells	Burkitt lymphoma	CVCL_0008	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

RFB4-SMPT-dgA [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Patients Enrolled	Eligible patients must have CD22+ (≥30%) B-cell NHL (excluding CLL, ALL, and hairy cell leukemia), measurable disease (excluding marrow-only involvement), and progression post-chemotherapy, with adequate organ function (CrCl >60 mL/min, bilirubin <1.5 mg/dL, EF ≥35% if prior doxorubicin).Key exclusions include HIV, CNS/pulmonary involvement, recent chemotherapy (<2 weeks), and transplant candidates. Required labs: SGPT <2x ULN, albumin >75% LLN, PS 0-2, and life expectancy ≥3 months. Click to Show/Hide
*Related Clinical Trial*
NCT Number	NCT00001271	Phase Status	PHASE1
Clinical Description	A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Anti-gp41 mAb ricin A chain [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.20 - 125 ng/mL
Method Description	Target cells (1000-2000) were plated in triplicate in 96-well flat bottom tissue culture plates in 100 uL tissue culture medium in the presence of the indicated concentration of mAb for 1 h at 37. The secondary immunotoxin, goat anti-human IgG conjugated to ricin A chain, was then added at a final concentration of 300 ng/mL in 100 uL, and the cells were incubated for 3 days. Click to Show/Hide
In Vitro Model	Human immunodeficiency virus type 1	HEK293/92UG cells	.
Experiment 2 Reporting the Activity Date of This ADC				[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	815 ng/mL
Method Description	Target cells (1000-2000) were plated in triplicate in 96-well flat bottom tissue culture plates in 100 uL tissue culture medium in the presence of the indicated concentration of mAb for 1 h at 37. The secondary immunotoxin, goat anti-human IgG conjugated to ricin A chain, was then added at a final concentration of 300 ng/mL in 100 uL, and the cells were incubated for 3 days. Click to Show/Hide
In Vitro Model	Human immunodeficiency virus type 1	H9/NL4-3 cells	.

References

Ref 1	Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J Immunol Methods. 1996 Oct 16;197(1-2):69-83.
Ref 2	A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
Ref 3	Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1. Vaccines (Basel). 2023 Apr 12;11(4):829. doi: 10.3390/vaccines11040829.